Mandate

Vinge advises BHG Group in acquisition of Nordic Nest

December 14, 2020 Employment and Benefits M&A

Vinge is advising BHG Group AB (publ) in connection with the acquisition of 97.6 per cent of the shares in Nordic Nest Group AB. The acquisition price corresponds to an enterprise value of SEK 1.8 billion.

Nordic Nest offers Scandinavian home decoration design online with customers in 70 countries, including the Nordics, Germany and South Korea. The company has approximately 220 employees and for the split fiscal year 2020/21, which ends on 31 March 2021, net sales are expected to be approximately SEK 1 billion and EBITDA is expected to amount to approximately MSEK 120.

BHG is the largest online actor within consumer trading in the Nordics and the largest actor in Europe within Home improvement, which includes both Do-It-Yourself and Home Furnishings. BHG’s e-trading business has 1,800 employees and includes more than 85 online destinations. The head office is situated in Malmö and the company conducts operations in most European countries. BHG is listed on Nasdaq Stockholm.

 

Vinge’s team consists of Kristian Ford together with, among others, Pär Remnelid, Philip ÅbergTilda HallDaniel Melander Björner and Emelie Svensäter Jerntorp.

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024